PerkinElmer predicts 12% growth in Q2

By The Science Advisory Board staff writers

July 13, 2020 -- PerkinElmer has announced an updated outlook for the second quarter of 2020, predicting 12% revenue growth.

For the quarter (end-July 5), the company said it anticipates roughly 12% growth in reported and organic revenue due to better-than-expected demand for COVID-19-related products. Products that aid with COVID-19 testing contributed approximately $190 million in revenue for the quarter, the company noted.

PerkinElmer announced it will release its full second-quarter results after market close on July 28.

PerkinElmer Q1 revenues edge up, profit edges down
In financial results for the first quarter, PerkinElmer saw revenues grow slightly, but net income slipped.
PerkinElmer launches new workflow tools
PerkinElmer has released a variety of new tools to help pharmaceutical, semiconductor, biomonitoring, and food and material labs improve their testing...
Shortage of RNA extraction kits threatens coronavirus testing
The weak link in the U.S. response to diagnostic testing for the novel coronavirus SARS-CoV-2 could be a shortage of RNA extraction kits. Fortunately,...

Copyright © 2020 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter